Cargando…
Permanent Pacemaker Placement Secondary to Remdesivir Induced Bradycardia: A Case Report
Remdesivir is approved by the FDA for the treatment of hospitalized coronavirus disease 2019 (COVID-19) patients. It is known to be associated with transient bradycardia that resolves after discontinuation of the drug. We present a case of a 71-year-old male with a history of congestive heart failur...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710722/ https://www.ncbi.nlm.nih.gov/pubmed/36465748 http://dx.doi.org/10.7759/cureus.30923 |
_version_ | 1784841426418270208 |
---|---|
author | Khan, Shahkar Mustafa, Ahmad Elhosseiny, Sherif M Rizvi, Taqi Lafferty, James |
author_facet | Khan, Shahkar Mustafa, Ahmad Elhosseiny, Sherif M Rizvi, Taqi Lafferty, James |
author_sort | Khan, Shahkar |
collection | PubMed |
description | Remdesivir is approved by the FDA for the treatment of hospitalized coronavirus disease 2019 (COVID-19) patients. It is known to be associated with transient bradycardia that resolves after discontinuation of the drug. We present a case of a 71-year-old male with a history of congestive heart failure, hypertension, and atrial flutter (rate controlled with carvedilol) presented for evaluation of worsening dyspnea, dry cough, and fatigue. His COVID-19 reverse transcription-polymerase chain reaction (RT-PCR) was positive and his chest x-ray showed right mid-lung opacity. Oxygen saturation was 88% on room air. He was started on dexamethasone and remdesivir. Bradycardia was noted on telemetry monitoring 48 hours after starting remdesivir. Carvedilol was discontinued, but the bradycardia persisted. Heart rate reached a nadir of 38 beats per minute (bpm) three days after completion of remdesivir therapy. Due to persistent bradycardia, he received a dual-chamber cardiac pacemaker without any immediate complications. Three months later, his pacemaker interrogation showed 99% ventricular pacing. We recommend that extra caution should be taken when initiating remdesivir therapy in individuals with baseline conduction abnormalities due to the possibility of persistent bradycardia. |
format | Online Article Text |
id | pubmed-9710722 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-97107222022-12-01 Permanent Pacemaker Placement Secondary to Remdesivir Induced Bradycardia: A Case Report Khan, Shahkar Mustafa, Ahmad Elhosseiny, Sherif M Rizvi, Taqi Lafferty, James Cureus Cardiology Remdesivir is approved by the FDA for the treatment of hospitalized coronavirus disease 2019 (COVID-19) patients. It is known to be associated with transient bradycardia that resolves after discontinuation of the drug. We present a case of a 71-year-old male with a history of congestive heart failure, hypertension, and atrial flutter (rate controlled with carvedilol) presented for evaluation of worsening dyspnea, dry cough, and fatigue. His COVID-19 reverse transcription-polymerase chain reaction (RT-PCR) was positive and his chest x-ray showed right mid-lung opacity. Oxygen saturation was 88% on room air. He was started on dexamethasone and remdesivir. Bradycardia was noted on telemetry monitoring 48 hours after starting remdesivir. Carvedilol was discontinued, but the bradycardia persisted. Heart rate reached a nadir of 38 beats per minute (bpm) three days after completion of remdesivir therapy. Due to persistent bradycardia, he received a dual-chamber cardiac pacemaker without any immediate complications. Three months later, his pacemaker interrogation showed 99% ventricular pacing. We recommend that extra caution should be taken when initiating remdesivir therapy in individuals with baseline conduction abnormalities due to the possibility of persistent bradycardia. Cureus 2022-10-31 /pmc/articles/PMC9710722/ /pubmed/36465748 http://dx.doi.org/10.7759/cureus.30923 Text en Copyright © 2022, Khan et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Cardiology Khan, Shahkar Mustafa, Ahmad Elhosseiny, Sherif M Rizvi, Taqi Lafferty, James Permanent Pacemaker Placement Secondary to Remdesivir Induced Bradycardia: A Case Report |
title | Permanent Pacemaker Placement Secondary to Remdesivir Induced Bradycardia: A Case Report |
title_full | Permanent Pacemaker Placement Secondary to Remdesivir Induced Bradycardia: A Case Report |
title_fullStr | Permanent Pacemaker Placement Secondary to Remdesivir Induced Bradycardia: A Case Report |
title_full_unstemmed | Permanent Pacemaker Placement Secondary to Remdesivir Induced Bradycardia: A Case Report |
title_short | Permanent Pacemaker Placement Secondary to Remdesivir Induced Bradycardia: A Case Report |
title_sort | permanent pacemaker placement secondary to remdesivir induced bradycardia: a case report |
topic | Cardiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710722/ https://www.ncbi.nlm.nih.gov/pubmed/36465748 http://dx.doi.org/10.7759/cureus.30923 |
work_keys_str_mv | AT khanshahkar permanentpacemakerplacementsecondarytoremdesivirinducedbradycardiaacasereport AT mustafaahmad permanentpacemakerplacementsecondarytoremdesivirinducedbradycardiaacasereport AT elhosseinysherifm permanentpacemakerplacementsecondarytoremdesivirinducedbradycardiaacasereport AT rizvitaqi permanentpacemakerplacementsecondarytoremdesivirinducedbradycardiaacasereport AT laffertyjames permanentpacemakerplacementsecondarytoremdesivirinducedbradycardiaacasereport |